The prepared NPs were able to disrupt the CML-related BCR–ABL gene without affecting the same gene in normal cells thereby improving the survival rate in a CML mouse model [102]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.